Multinational economic evaluations of pharmaceuticals

Lancet

Volumn 360, Issue 9336, 2002, Pages 816-

  Smith, Scott R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; CAPITAL; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; INSURANCE; LIFE CYCLE; MANAGEMENT; MARKET; NOTE; PRIORITY JOURNAL;

EID: 0037077836     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11011-7     Document Type: Note

References (8)

1. Bloor K., Maynard A., Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry. BMJ. 313:1996;33-35.
2. Ioannides-Demos L.L., Ibrahim J.E., McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics. 20:2002;577-591.
3. Casadio Tarabusi C., Vickery G. Globalization in the pharmaceutical industry: part I. Int J Health Serv. 28:1998;67-105.
4. Casadio Tarabusi C., Vickery G. Globalization in the pharmaceutical industry: part II. Int J Health Serv. 28:1998;281-303.
5. Pang F. Design, analysis and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics. 20:2002;75-90.
6. Anis A.H., Wen Q. Price regulation of pharmaceuticals in Canada. J Health Econ. 17:1998;21-38.
7. Schweitzer S.O. Pricing pharmaceuticals in a world environment. Pharmaceutical economics and policy. 1997;137-151 Oxford University Press, New York.
8. Tagert J. The development of the world pharmaceutical industry. The world pharmaceutical industry. 1993;33 Routledge, London.